SLC5A2 and atherosclerosis: Among patients with comorbid DM and ASCVD, glucagon-like 1 receptor agonists (GLP1-RAs) and sodium glucose cotransporter 2 (SGLT2) inhibitors are recommended to improve CVD and cardiorenal outcomes (83, 84).